Alzheimer’s studies show the key role of brain receptor Sigma-1 in the development of the disease, Anavex says



[ad_1]

Anavex Life Sciences has published a study demonstrating the role of the sigma-1 receptor in Alzheimer's disease. The data it contains support the development of compounds from the New York-based company that stimulate this receptor as a way to treat the disease.

The study, "Sigma-1 receptor agonists induce oxidative stress in mitochondria and improve complex I activity in physiological condition, but protect against pathological oxidative stress," appeared in the journal Neurotoxicity Research. He showed that the sigma-1 enhancer compounds act as antioxidants and protect the energy-generating structures called mitochondria in conditions such as Alzheimer's.

Meanwhile, another study, "Amyloid toxicity increases after pharmacological or genetic invalidation of the [sigma] 1 receptor", published in the journal Behavioral Brain Research showed that the lack of sigma-1 worsens toxicity caused by amyloid proteins.

"Both findings are consistent with the concept that sigma-1 receptor activity appears to be essential for cell survival under stress, with the ability to counteract the different manifestations of Alzheimer's disease and other neurodegenerative pathologies," he said. In a press release, Dr. Tangui Maurice, the lead author of both studies and a professor at the French institute of scientific research INSERM.

Researchers believe that abnormal mitochondrial processes and linked oxidative damage are key to driving the disease in several neurogenic generative conditions. People with Alzheimer's disease show signs of oxidative damage long before they have substantial amyloid plaques, which are considered a telltale sign of the disease.

The article Neurotoxicity Research provided information on the mechanisms of action of three Anavex compounds developed for the treatment of Alzheimer's disease and other neurodegenerative diseases. It suggests that all three can act as potent neuroprotectors in people with the disease.

The second publication indicated that if these neuroprotective effects are lacking, amyloid accumulation worsened learning and memory problems, as well as other disease markers, in mouse models. of Alzheimer's

"These results appear to further validate sigma-1 receptor agonism as a therapeutic target for the treatment of neurodegenerative diseases," said Dr. Christopher U. Missling, president and CEO of Anavex.

One of Anavex's compounds, Anavex 2-73, is in clinical development for Alzheimer's, and the company recently announced that it will soon launch a Phase 2 trial of the drug candidate.

The first data from the Phase 1 study of the compound indicated that people in the highest dose group actually improved with the treatment, raising hopes that Anavex 2-73 could break the negative trend of developmental failures of drugs for Alzheimer's.

[ad_2]
Source link

Leave a Reply

Your email address will not be published.